Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Receivables (2016 - 2025)

Guided Therapeutics' Receivables history spans 16 years, with the latest figure at $2000.0 for Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $2000.0; the TTM value through Sep 2025 reached $2000.0, changed N/A, while the annual FY2024 figure was $3000.0, 59.69% down from the prior year.
  • Receivables for Q3 2025 was $2000.0 at Guided Therapeutics, down from $8000.0 in the prior quarter.
  • Across five years, Receivables topped out at $150785.0 in Q2 2022 and bottomed at $2000.0 in Q2 2024.
  • The 5-year median for Receivables is $16471.0 (2021), against an average of $52288.6.
  • The largest annual shift saw Receivables surged 450.97% in 2022 before it crashed 95.36% in 2023.
  • A 5-year view of Receivables shows it stood at $126000.0 in 2021, then decreased by 29.13% to $89296.0 in 2022, then tumbled by 92.16% to $7000.0 in 2023, then plummeted by 57.14% to $3000.0 in 2024, then tumbled by 33.33% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Receivables are $2000.0 (Q3 2025), $8000.0 (Q2 2025), and $2000.0 (Q1 2025).